Rogers Sugar (TSE:RSI) Given New C$5.00 Price Target at BMO Capital Markets

Share on StockTwits

Rogers Sugar (TSE:RSI) had its price objective lowered by BMO Capital Markets from C$5.50 to C$5.00 in a research note issued to investors on Friday morning, BayStreet.CA reports.

Other analysts have also issued reports about the stock. Desjardins cut their target price on shares of Rogers Sugar from C$6.00 to C$5.25 in a research note on Friday. National Bank Financial cut their target price on shares of Rogers Sugar from C$5.50 to C$5.25 and set a sector perform rating for the company in a research note on Friday.

RSI stock opened at C$5.36 on Friday. Rogers Sugar has a 12 month low of C$5.23 and a 12 month high of C$6.17. The firm has a market capitalization of $562.84 million and a price-to-earnings ratio of 13.71. The company’s 50 day simple moving average is C$5.67. The company has a current ratio of 2.23, a quick ratio of 0.80 and a debt-to-equity ratio of 100.53.

About Rogers Sugar

Rogers Sugar Inc, through its subsidiary, Lantic Inc, engages in refining, packaging, and marketing sugar and maple products. It offers granulated, plantation raw, brown, organic, icing, maple, stevia, smart sweetener blend, and coconut sugar, as well as syrups, jam and jelly mixes, iced tea mixes, and hot chocolate mixes.

See Also: Do investors pay a separate front-end load every time they buy additional shares?

Receive News & Ratings for Rogers Sugar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rogers Sugar and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SpartanNash  Lifted to “Hold” at Pivotal Research
SpartanNash Lifted to “Hold” at Pivotal Research
SpartanNash  Lifted to “Hold” at ValuEngine
SpartanNash Lifted to “Hold” at ValuEngine
ValuEngine Lowers Sportsman’s Warehouse  to Sell
ValuEngine Lowers Sportsman’s Warehouse to Sell
Sorrento Therapeutics  Raised to “Hold” at Zacks Investment Research
Sorrento Therapeutics Raised to “Hold” at Zacks Investment Research
Sierra Oncology  Upgraded at Zacks Investment Research
Sierra Oncology Upgraded at Zacks Investment Research
Zacks Investment Research Lowers Sierra Oncology  to Hold
Zacks Investment Research Lowers Sierra Oncology to Hold


© 2006-2019 Ticker Report